-
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Category 1 drug yiqibuvir. The non-structural protein 5B (NS5B) inhibitor is approved for use in combination with netanasvir in adult chronic hepatitis C virus (HCV) infections of genotypes…
-
YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with compatriot firm DP Technology, with the aim of leveraging artificial intelligence (AI) to bolster the biopharmaceutical industry. This strategic collaboration is an extension of an existing partnership between the two companies, which saw the establishment…
-
Tonghua Dongbao Pharmaceuticals Begins Clinical Trial for Xultophy Biosimilar
•
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the dosing of the first patient in a Phase I clinical study for its insulin degludec and liraglutide combination drug. This molecule is a biosimilar version of Novo Nordisk’s Xultophy, the first compound preparation to combine a basal insulin…
-
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
•
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in March 2022, has been finalized and is open for public feedback from April 24 to 26. A total of 49 insulin products from 13 manufacturers have been awarded renewed tender spots, with a total contracted…
-
YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials
•
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB…
-
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
•
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house developed insulin aspart (specification 3ml: 300 units, refill) has been approved for marketing by the National Medical Products Administration (NMPA). This approval marks a significant milestone in the company’s efforts to expand its presence in…
-
YiChang HEC Reports Strong Recovery in 2022 Interim Results
•
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1%…
-
Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta
•
The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant Boehringer Ingelheim (BI) in a patent infringement dispute with HEC and its affiliate Yichang HEC Changjiang Pharmaceutical Co., Ltd. The ruling centers on BI’s patent protecting the linagliptin compound used in its Trajenta diabetes drug.…
